Supernus Pharmaceuticals SUPN Oxtellar XR — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's oxtellar xr — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's oxtellar XR — total revenues?
- Supernus Pharmaceuticals (SUPN) reported oxtellar XR — total revenues of $7.42M in Q1 2026.
- How has Supernus Pharmaceuticals's oxtellar XR — total revenues changed year-over-year?
- Supernus Pharmaceuticals's oxtellar XR — total revenues decreased by 27.2% year-over-year, from $10.2M to $7.42M.
- What is the long-term trend for Supernus Pharmaceuticals's oxtellar XR — total revenues?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's oxtellar XR — total revenues has grown at a -22.1% compound annual growth rate (CAGR), from $110.71M to $40.7M.
- What does oxtellar XR — total revenues mean?
- This metric represents the total gross revenue generated from the sales of a specific pharmaceutical product within the company's neuroscience portfolio. It serves as a key indicator of the product's market adoption, commercial performance, and contribution to the company's overall top-line growth. Tracking this revenue stream helps investors assess the lifecycle stage and competitive positioning of the therapeutic asset.